Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease

P. E. Bendheim; B. Poeggeler; E. Neria; V. Ziv; M. A. Pappolla; D. G. Chain

doi:10.1007/s12031-002-0036-0

Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease

P. E. Bendheim, B. Poeggeler, E. Neria, V. Ziv, M. A. Pappolla, D. G. Chain

Research output: Contribution to journal › Article › peer-review

111 Scopus citations

Abstract

The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.

Original language	English (US)
Pages (from-to)	213-217
Number of pages	5
Journal	Journal of Molecular Neuroscience
Volume	19
Issue number	1-2
DOIs	https://doi.org/10.1007/s12031-002-0036-0
State	Published - 2002
Externally published	Yes

Keywords

Alzheimer's disease
Beta-amyloid
Indole-3-propionic acid
Oxidative stress

ASJC Scopus subject areas

Cellular and Molecular Neuroscience

Access to Document

10.1007/s12031-002-0036-0

Cite this

@article{b608d121b18245be8a02286fc887c10d,

title = "Development of indole-3-propionic acid (OXIGON{\texttrademark}) for Alzheimer's disease",

abstract = "The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON{\texttrademark}) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.",

keywords = "Alzheimer's disease, Beta-amyloid, Indole-3-propionic acid, Oxidative stress",

author = "Bendheim, {P. E.} and B. Poeggeler and E. Neria and V. Ziv and Pappolla, {M. A.} and Chain, {D. G.}",

year = "2002",

doi = "10.1007/s12031-002-0036-0",

language = "English (US)",

volume = "19",

pages = "213--217",

journal = "Molecular and Chemical Neuropathology",

issn = "0895-8696",

publisher = "Humana Press",

number = "1-2",

}

TY - JOUR

T1 - Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease

AU - Bendheim, P. E.

AU - Poeggeler, B.

AU - Neria, E.

AU - Ziv, V.

AU - Pappolla, M. A.

AU - Chain, D. G.

PY - 2002

Y1 - 2002

N2 - The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.

AB - The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON™) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.

KW - Alzheimer's disease

KW - Beta-amyloid

KW - Indole-3-propionic acid

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=0036675722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036675722&partnerID=8YFLogxK

U2 - 10.1007/s12031-002-0036-0

DO - 10.1007/s12031-002-0036-0

M3 - Article

C2 - 12212784

AN - SCOPUS:0036675722

SN - 0895-8696

VL - 19

SP - 213

EP - 217

JO - Molecular and Chemical Neuropathology

JF - Molecular and Chemical Neuropathology

IS - 1-2

ER -

Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this